Language selection

Search

Details for: YERVOY

Company: BRISTOL-MYERS SQUIBB CANADA

DIN DIN name Active Ingredient(s) Strength Dosage Form Route of Administration
02379384YERVOYIPILIMUMAB5 MG / MLLIQUIDINTRAVENOUS
Search Reported Side Effects Report a Side Effect

Summary Reports

Summary Basis of Decision
Regulatory Decision Summary
Regulatory Decision Summary
Summary Safety Review - YERVOY (ipilimumab) - Posterior Reversible Encephalopathy Syndrome (PRES)
Summary Safety Review - YERVOY (ipilimumab) - Assessing the Potential Risk of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
Summary Safety Review - Opdivo (nivolumab) and Yervoy (ipilimumab) used alone, or in combination - Assessing the potential risk of Hemophagocytic Lymphohistiocytosis (HLH)

Consumer Information

The Consumer Information is not yet available in the Drug and Health Product Register. Try searching on the active ingredient(s) to find other similar products.

Date modified: